Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies
Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2000 |
|---|
| Umfang: |
4 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: World journal of surgery - 1977, 24(2000) vom: Okt., Seite 1211-1214 |
| Übergeordnetes Werk: |
volume:24 ; year:2000 ; month:10 ; pages:1211-1214 ; extent:4 |
| Links: |
|---|
| Katalog-ID: |
NLEJ207270457 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ207270457 | ||
| 003 | DE-627 | ||
| 005 | 20230506102112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s2000 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ207270457 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies |
| 264 | 1 | |c 2000 | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well as quality of life. Indeed, we are still at an embryonic stage in understanding how cancers originate, whether defense mechanisms exist that can recognize these cancers and recognize them when they first develop, when cancers metastasize during their development, whether we have methods that are sufficiently accurate to distinguish between organ-confined and regional extension or spread of disease, and the means by which we can identify cancers that are likely to remain organ-confined and distinguish them from those that are predestined to metastasize. If we are to be successful in the assessment and treatment of various urologic cancers, these questions must be answered. Many new methods of assessment and treatment are being explored that in themselves may provide some answers. The present discussion focuses on these issues, on how they may lead to further understanding of the unique biology of many of these tumors, and what we may expect in terms of increased longevity and improved quality of life as we attempt to cure patients of their disease. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Droller, Michael J. |4 oth | |
| 773 | 0 | 8 | |i in |t World journal of surgery |d 1977 |g 24(2000) vom: Okt., Seite 1211-1214 |w (DE-627)NLEJ188985433 |w (DE-600)1463296-2 |x 1432-2323 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2000 |g month:10 |g pages:1211-1214 |g extent:4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s002680010207 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2000 |c 10 |h 1211-1214 |g 4 | ||
| matchkey_str |
article:14322323:2000----::rlgitewnyiscnuyoivsvtreetetetf |
|---|---|
| hierarchy_sort_str |
2000 |
| publishDate |
2000 |
| allfields |
(DE-627)NLEJ207270457 DE-627 ger DE-627 rakwb eng Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies 2000 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well as quality of life. Indeed, we are still at an embryonic stage in understanding how cancers originate, whether defense mechanisms exist that can recognize these cancers and recognize them when they first develop, when cancers metastasize during their development, whether we have methods that are sufficiently accurate to distinguish between organ-confined and regional extension or spread of disease, and the means by which we can identify cancers that are likely to remain organ-confined and distinguish them from those that are predestined to metastasize. If we are to be successful in the assessment and treatment of various urologic cancers, these questions must be answered. Many new methods of assessment and treatment are being explored that in themselves may provide some answers. The present discussion focuses on these issues, on how they may lead to further understanding of the unique biology of many of these tumors, and what we may expect in terms of increased longevity and improved quality of life as we attempt to cure patients of their disease. Springer Online Journal Archives 1860-2002 Droller, Michael J. oth in World journal of surgery 1977 24(2000) vom: Okt., Seite 1211-1214 (DE-627)NLEJ188985433 (DE-600)1463296-2 1432-2323 nnns volume:24 year:2000 month:10 pages:1211-1214 extent:4 http://dx.doi.org/10.1007/s002680010207 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 24 2000 10 1211-1214 4 |
| spelling |
(DE-627)NLEJ207270457 DE-627 ger DE-627 rakwb eng Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies 2000 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well as quality of life. Indeed, we are still at an embryonic stage in understanding how cancers originate, whether defense mechanisms exist that can recognize these cancers and recognize them when they first develop, when cancers metastasize during their development, whether we have methods that are sufficiently accurate to distinguish between organ-confined and regional extension or spread of disease, and the means by which we can identify cancers that are likely to remain organ-confined and distinguish them from those that are predestined to metastasize. If we are to be successful in the assessment and treatment of various urologic cancers, these questions must be answered. Many new methods of assessment and treatment are being explored that in themselves may provide some answers. The present discussion focuses on these issues, on how they may lead to further understanding of the unique biology of many of these tumors, and what we may expect in terms of increased longevity and improved quality of life as we attempt to cure patients of their disease. Springer Online Journal Archives 1860-2002 Droller, Michael J. oth in World journal of surgery 1977 24(2000) vom: Okt., Seite 1211-1214 (DE-627)NLEJ188985433 (DE-600)1463296-2 1432-2323 nnns volume:24 year:2000 month:10 pages:1211-1214 extent:4 http://dx.doi.org/10.1007/s002680010207 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 24 2000 10 1211-1214 4 |
| allfields_unstemmed |
(DE-627)NLEJ207270457 DE-627 ger DE-627 rakwb eng Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies 2000 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well as quality of life. Indeed, we are still at an embryonic stage in understanding how cancers originate, whether defense mechanisms exist that can recognize these cancers and recognize them when they first develop, when cancers metastasize during their development, whether we have methods that are sufficiently accurate to distinguish between organ-confined and regional extension or spread of disease, and the means by which we can identify cancers that are likely to remain organ-confined and distinguish them from those that are predestined to metastasize. If we are to be successful in the assessment and treatment of various urologic cancers, these questions must be answered. Many new methods of assessment and treatment are being explored that in themselves may provide some answers. The present discussion focuses on these issues, on how they may lead to further understanding of the unique biology of many of these tumors, and what we may expect in terms of increased longevity and improved quality of life as we attempt to cure patients of their disease. Springer Online Journal Archives 1860-2002 Droller, Michael J. oth in World journal of surgery 1977 24(2000) vom: Okt., Seite 1211-1214 (DE-627)NLEJ188985433 (DE-600)1463296-2 1432-2323 nnns volume:24 year:2000 month:10 pages:1211-1214 extent:4 http://dx.doi.org/10.1007/s002680010207 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 24 2000 10 1211-1214 4 |
| allfieldsGer |
(DE-627)NLEJ207270457 DE-627 ger DE-627 rakwb eng Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies 2000 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well as quality of life. Indeed, we are still at an embryonic stage in understanding how cancers originate, whether defense mechanisms exist that can recognize these cancers and recognize them when they first develop, when cancers metastasize during their development, whether we have methods that are sufficiently accurate to distinguish between organ-confined and regional extension or spread of disease, and the means by which we can identify cancers that are likely to remain organ-confined and distinguish them from those that are predestined to metastasize. If we are to be successful in the assessment and treatment of various urologic cancers, these questions must be answered. Many new methods of assessment and treatment are being explored that in themselves may provide some answers. The present discussion focuses on these issues, on how they may lead to further understanding of the unique biology of many of these tumors, and what we may expect in terms of increased longevity and improved quality of life as we attempt to cure patients of their disease. Springer Online Journal Archives 1860-2002 Droller, Michael J. oth in World journal of surgery 1977 24(2000) vom: Okt., Seite 1211-1214 (DE-627)NLEJ188985433 (DE-600)1463296-2 1432-2323 nnns volume:24 year:2000 month:10 pages:1211-1214 extent:4 http://dx.doi.org/10.1007/s002680010207 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 24 2000 10 1211-1214 4 |
| allfieldsSound |
(DE-627)NLEJ207270457 DE-627 ger DE-627 rakwb eng Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies 2000 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well as quality of life. Indeed, we are still at an embryonic stage in understanding how cancers originate, whether defense mechanisms exist that can recognize these cancers and recognize them when they first develop, when cancers metastasize during their development, whether we have methods that are sufficiently accurate to distinguish between organ-confined and regional extension or spread of disease, and the means by which we can identify cancers that are likely to remain organ-confined and distinguish them from those that are predestined to metastasize. If we are to be successful in the assessment and treatment of various urologic cancers, these questions must be answered. Many new methods of assessment and treatment are being explored that in themselves may provide some answers. The present discussion focuses on these issues, on how they may lead to further understanding of the unique biology of many of these tumors, and what we may expect in terms of increased longevity and improved quality of life as we attempt to cure patients of their disease. Springer Online Journal Archives 1860-2002 Droller, Michael J. oth in World journal of surgery 1977 24(2000) vom: Okt., Seite 1211-1214 (DE-627)NLEJ188985433 (DE-600)1463296-2 1432-2323 nnns volume:24 year:2000 month:10 pages:1211-1214 extent:4 http://dx.doi.org/10.1007/s002680010207 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 24 2000 10 1211-1214 4 |
| language |
English |
| source |
in World journal of surgery 24(2000) vom: Okt., Seite 1211-1214 volume:24 year:2000 month:10 pages:1211-1214 extent:4 |
| sourceStr |
in World journal of surgery 24(2000) vom: Okt., Seite 1211-1214 volume:24 year:2000 month:10 pages:1211-1214 extent:4 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
World journal of surgery |
| authorswithroles_txt_mv |
Droller, Michael J. @@oth@@ |
| publishDateDaySort_date |
2000-10-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188985433 |
| id |
NLEJ207270457 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ207270457</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506102112.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s2000 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ207270457</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well as quality of life. Indeed, we are still at an embryonic stage in understanding how cancers originate, whether defense mechanisms exist that can recognize these cancers and recognize them when they first develop, when cancers metastasize during their development, whether we have methods that are sufficiently accurate to distinguish between organ-confined and regional extension or spread of disease, and the means by which we can identify cancers that are likely to remain organ-confined and distinguish them from those that are predestined to metastasize. If we are to be successful in the assessment and treatment of various urologic cancers, these questions must be answered. Many new methods of assessment and treatment are being explored that in themselves may provide some answers. The present discussion focuses on these issues, on how they may lead to further understanding of the unique biology of many of these tumors, and what we may expect in terms of increased longevity and improved quality of life as we attempt to cure patients of their disease.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Droller, Michael J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">World journal of surgery</subfield><subfield code="d">1977</subfield><subfield code="g">24(2000) vom: Okt., Seite 1211-1214</subfield><subfield code="w">(DE-627)NLEJ188985433</subfield><subfield code="w">(DE-600)1463296-2</subfield><subfield code="x">1432-2323</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2000</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:1211-1214</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s002680010207</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2000</subfield><subfield code="c">10</subfield><subfield code="h">1211-1214</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188985433 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-2323 |
| topic_title |
Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m j d mj mjd |
| hierarchy_parent_title |
World journal of surgery |
| hierarchy_parent_id |
NLEJ188985433 |
| hierarchy_top_title |
World journal of surgery |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188985433 (DE-600)1463296-2 |
| title |
Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies |
| spellingShingle |
Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies |
| ctrlnum |
(DE-627)NLEJ207270457 |
| title_full |
Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies |
| journal |
World journal of surgery |
| journalStr |
World journal of surgery |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2000 |
| contenttype_str_mv |
zzz |
| container_start_page |
1211 |
| container_volume |
24 |
| physical |
4 |
| format_se |
Elektronische Aufsätze |
| title_sort |
urology in the twenty-first century: noninvasive targeted treatments for urologic malignancies |
| title_auth |
Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies |
| abstract |
Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well as quality of life. Indeed, we are still at an embryonic stage in understanding how cancers originate, whether defense mechanisms exist that can recognize these cancers and recognize them when they first develop, when cancers metastasize during their development, whether we have methods that are sufficiently accurate to distinguish between organ-confined and regional extension or spread of disease, and the means by which we can identify cancers that are likely to remain organ-confined and distinguish them from those that are predestined to metastasize. If we are to be successful in the assessment and treatment of various urologic cancers, these questions must be answered. Many new methods of assessment and treatment are being explored that in themselves may provide some answers. The present discussion focuses on these issues, on how they may lead to further understanding of the unique biology of many of these tumors, and what we may expect in terms of increased longevity and improved quality of life as we attempt to cure patients of their disease. |
| abstractGer |
Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well as quality of life. Indeed, we are still at an embryonic stage in understanding how cancers originate, whether defense mechanisms exist that can recognize these cancers and recognize them when they first develop, when cancers metastasize during their development, whether we have methods that are sufficiently accurate to distinguish between organ-confined and regional extension or spread of disease, and the means by which we can identify cancers that are likely to remain organ-confined and distinguish them from those that are predestined to metastasize. If we are to be successful in the assessment and treatment of various urologic cancers, these questions must be answered. Many new methods of assessment and treatment are being explored that in themselves may provide some answers. The present discussion focuses on these issues, on how they may lead to further understanding of the unique biology of many of these tumors, and what we may expect in terms of increased longevity and improved quality of life as we attempt to cure patients of their disease. |
| abstract_unstemmed |
Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well as quality of life. Indeed, we are still at an embryonic stage in understanding how cancers originate, whether defense mechanisms exist that can recognize these cancers and recognize them when they first develop, when cancers metastasize during their development, whether we have methods that are sufficiently accurate to distinguish between organ-confined and regional extension or spread of disease, and the means by which we can identify cancers that are likely to remain organ-confined and distinguish them from those that are predestined to metastasize. If we are to be successful in the assessment and treatment of various urologic cancers, these questions must be answered. Many new methods of assessment and treatment are being explored that in themselves may provide some answers. The present discussion focuses on these issues, on how they may lead to further understanding of the unique biology of many of these tumors, and what we may expect in terms of increased longevity and improved quality of life as we attempt to cure patients of their disease. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies |
| url |
http://dx.doi.org/10.1007/s002680010207 |
| remote_bool |
true |
| author2 |
Droller, Michael J. |
| author2Str |
Droller, Michael J. |
| ppnlink |
NLEJ188985433 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| up_date |
2024-07-06T09:15:04.128Z |
| _version_ |
1803820522936467456 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ207270457</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506102112.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s2000 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ207270457</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Urology in the Twenty-first Century: Noninvasive Targeted Treatments for Urologic Malignancies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Notwithstanding the major advances that have been made in the treatment of bladder cancer, prostate cancer, and kidney cancer, much remains to be done if we are to translate the gains that have been made in "disease-free survival" into actual survival in terms of quantity as well as quality of life. Indeed, we are still at an embryonic stage in understanding how cancers originate, whether defense mechanisms exist that can recognize these cancers and recognize them when they first develop, when cancers metastasize during their development, whether we have methods that are sufficiently accurate to distinguish between organ-confined and regional extension or spread of disease, and the means by which we can identify cancers that are likely to remain organ-confined and distinguish them from those that are predestined to metastasize. If we are to be successful in the assessment and treatment of various urologic cancers, these questions must be answered. Many new methods of assessment and treatment are being explored that in themselves may provide some answers. The present discussion focuses on these issues, on how they may lead to further understanding of the unique biology of many of these tumors, and what we may expect in terms of increased longevity and improved quality of life as we attempt to cure patients of their disease.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Droller, Michael J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">World journal of surgery</subfield><subfield code="d">1977</subfield><subfield code="g">24(2000) vom: Okt., Seite 1211-1214</subfield><subfield code="w">(DE-627)NLEJ188985433</subfield><subfield code="w">(DE-600)1463296-2</subfield><subfield code="x">1432-2323</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:24</subfield><subfield code="g">year:2000</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:1211-1214</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/s002680010207</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">24</subfield><subfield code="j">2000</subfield><subfield code="c">10</subfield><subfield code="h">1211-1214</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| score |
7.402733 |